Hull and East Yorkshire Eye Hospital, Fountain Street, Anlaby Road, Kingston-upon-hull, Yorkshire HU3 2JZ, United Kingdom.

A 46-year-old woman presented with a peripheral vasoproliferative tumor. The tumor was treated with one session of photodynamic therapy with 6 mg/m2 body surface area of verteporfin and a dose of 100 J/cm2 delivered in 83 seconds. At the 10-month follow-up examination, involution of the vasoproliferative tumor was seen with improvement of best-corrected visual acuity to 20/80. Photodynamic therapy is an effective treatment option in cases of exudative vasoproliferative tumors. Great variability exists in the parameters used to treat vasoproliferative tumors.

Share This

Department of Oncology, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark, ggundgaard@hotmail.com.

BACKGROUND: The past years’ therapy for colorectal cancer has evolved rapidly with the introduction of novel cytotoxic agents such as irinotecan, capecitabine and oxaliplatin. Further advances have been achieved with the integration of targeted agents such as bevacizumab, cetuximab and recently, panitumumab. As a result, third-line treatment is now a necessary step in the optimal treatment of patients with metastatic colorectal cancer (MCRC). MATERIALS AND METHODS: We conducted a literature review of English language publications on third-line therapy for MCRC from January 2000 to April 2007. Data on median overall survival (mOS), median time to progression (mTTP) and response rate were recorded. RESULTS: We found 27 articles and 22 abstracts to fulfil the criteria. Patients who received regimens containing oxaliplatin and infusional 5-fluorouracil (5-FU) demonstrated mTTP up to 7 months and a mOS of 16 months. With irinotecan and 5-FU, mOS around 8 months were reported and with cetuximab combined with irinotecan, the highest mOS was 9.8 months. CONCLUSION: Third-line therapy in advanced colorectal cancer may improve mOS for patients with MCRC. Therefore, randomized studies should be conducted in the future.

PMID: 17786445 [PubMed - in process]

Share This

Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA 90502, USA.

Avemar, the product of industrial fermentation of wheat germ, possesses unique cancer-fighting characteristics. Taken orally, Avemar can inhibit metastatic tumor dissemination and proliferation during and after chemotherapy, surgery, or radiation. Benefits of Avemar treatment have been shown in various human cancers, in cultures of in vitro grown cancer cells, in the prevention of chemical carcinogenesis, and also in some autoimmune conditions. This document reviews the clinical and experimental results obtained with this extract so far.
More Data :

New Cancer Research
Read the rest…

Share This